Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Gross Profit (2019 - 2025)

Coherus Oncology's Gross Profit history spans 7 years, with the latest figure at $8.7 million for Q4 2025.

  • For Q4 2025, Gross Profit fell 89.48% year-over-year to $8.7 million; the TTM value through Dec 2025 reached $28.4 million, down 82.29%, while the annual FY2025 figure was $28.4 million, 60.56% up from the prior year.
  • Gross Profit for Q4 2025 was $8.7 million at Coherus Oncology, up from $7.8 million in the prior quarter.
  • Across five years, Gross Profit topped out at $82.7 million in Q4 2024 and bottomed at $869000.0 in Q1 2024.
  • The 5-year median for Gross Profit is $32.5 million (2022), against an average of $34.8 million.
  • The largest YoY upside for Gross Profit was 1088.75% in 2024 against a maximum downside of 94.42% in 2024.
  • A 5-year view of Gross Profit shows it stood at $61.2 million in 2021, then tumbled by 49.14% to $31.2 million in 2022, then plummeted by 77.67% to $7.0 million in 2023, then skyrocketed by 1088.75% to $82.7 million in 2024, then plummeted by 89.48% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Gross Profit are $8.7 million (Q4 2025), $7.8 million (Q3 2025), and $6.9 million (Q2 2025).